Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7PX3O
|
|||
| Drug Name |
TBI-223
|
|||
| Synonyms |
TBI-223; UNII-B4RS1V5YSP; B4RS1V5YSP; 2071265-08-0; TBI 223; Carbamic acid, N-(((5S)-3-(3-fluoro-4-(2-oxa-6-azaspiro(3.3)hept-6-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, methyl ester; methyl N-[[(5S)-3-[3-fluoro-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate; CHEMBL5201490; SCHEMBL18408931; GTPL13029; AKOS040755770; AT39355; MS-25829; HY-139398; CS-0200359; methyl (S)-((3-(3-fluoro-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)carbamate; methyl N-[[(5S)-3-[3-fluoro-4-(6-oxa-2-azaspiro[3.3]heptan-2-yl)phenyl]-2-oxo-oxazolidin-5-yl]methyl]carbamate
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Tuberculosis [ICD-11: 1B10-1B14] | Phase 1 | [1] | |
| Company |
TB
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H20FN3O5
|
|||
| Canonical SMILES |
COC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CC4(C3)COC4)F
|
|||
| InChI |
InChI=1S/C17H20FN3O5/c1-24-15(22)19-5-12-6-21(16(23)26-12)11-2-3-14(13(18)4-11)20-7-17(8-20)9-25-10-17/h2-4,12H,5-10H2,1H3,(H,19,22)/t12-/m0/s1
|
|||
| InChIKey |
ZNBRXLSWXJKKLJ-LBPRGKRZSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03758612) A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) With a Food Effect Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adult Participants. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.